OKYO Pharma CEO Shares Promising Findings on Dry Eye Disease and Neuropathic Pain Treatment

OKYO Pharma CEO Shares Promising Findings on Dry Eye Disease and Neuropathic Pain Treatment

Key Takeaways (TLDR)

• OK-101 shows statistically significant reduction in ocular pain, giving OKYO Pharma a potential edge in dry eye treatment market.

• OK-101, a long-acting drug candidate developed using membrane-anchored-peptide technology, targets Chemerin 23 receptor to reduce neuropathic pain.

• OK-101's Phase 2 trial results offer hope for relief to patients suffering from excruciating neuropathic corneal pain, addressing a therapeutic gap.

• OK-101, a novel long-acting drug candidate, has shown anti-inflammatory and pain-reducing efficacy in mouse models of dry eye disease and corneal neuropathic pain.

Why it Matters

This news matters as it highlights a potential breakthrough in dry eye disease and neuropathic corneal pain treatment, offering hope to patients with no FDA-approved treatments available.

Summary

OKYO Pharma Ltd CEO Gary Jacobs shares key findings from a Phase 2 clinical trial evaluating the safety and efficacy of OK-101 ophthalmic solution in patients with dry eye disease. The trial involved 240 patients and the drug candidate has shown anti-inflammatory and pain-reducing efficacy in mouse models of dry eye disease and corneal neuropathic pain.

The findings include a statistically significant reduction in ocular pain and improvement in Tear Film Break-Up Time, with plans for a Phase II trial specifically targeting neuropathic corneal pain, a condition with no FDA-approved treatments. This development aims to offer relief to patients suffering from this severe condition.

This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is OKYO Pharma CEO Shares Promising Findings on Dry Eye Disease and Neuropathic Pain Treatment.